- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00782002
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
September 29, 2010 updated by: Eli Lilly and Company
Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available
The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.
Study Overview
Detailed Description
The purpose of this study will be to establish the safety profile and the maximum tolerated dose (MTD) of the anti-VEGFR-1 monoclonal antibody IMC-18F1 administered weekly, every other week, or every three weeks in patients with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- ImClone Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- ImClone Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with histopathologically-documented, measurable or non measurable {evaluable}, advanced solid tumors refractory to standard therapy or for which no standard therapy is available (see Section 10.2, Tumor Response, for the definition of measurable and non measurable {evaluable} disease).
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 at study entry.
- Able to provide written informed consent.
- Age 18 years or older.
- A life expectancy of >3 months.
Adequate hematologic function, as defined by:
- an absolute neutrophil count ≥1500/mm3
- a hemoglobin level ≥ 9gm/dL
- a platelet count ≥100,000/mm3
Adequate hepatic function, as defined by:
- a total bilirubin level ≤1.5 x the ULN
- aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 x the ULN or ≤5 x the ULN if known liver metastases
- Adequate renal function, as defined by a serum creatinine level ≤1.5 x the ULN.
- Use of effective contraception (per the institutional standard), if procreative potential exists.
- Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy (palliative radiation therapy is allowed).
- Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.
Exclusion Criteria:
- Patients who have had chemotherapy or therapeutic radiotherapy within 28 days prior to entering the study or patients with ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
Uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection requiring parenteral antibiotics
- symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease)
- left ventricular ejection fraction (LVEF) of <50%. If a baseline MUGA shows a <50% ejection fraction, then a confirmatory ultrasound should be performed. If it is <50%, the patient is excluded from the study
- unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
- uncontrolled hypertension (systolic blood pressure >150 mm Hg, diastolic blood pressure >100 mm Hg, found on two consecutive measurements separated by a 1-week period despite adequate medical support)
- clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [Common Terminology Criteria for Adverse Events {CTCAE}, Version 3.0, grade 3] or asymptomatic sustained ventricular tachycardia)
- uncontrolled diabetes
- psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
- Patients with progressive or symptomatic brain or leptomeningeal metastases. (Patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids; anti-seizure medications are allowed).
- A serious or nonhealing active wound, ulcer, or bone fracture.
- Known human immunodeficiency virus positivity.
- A major surgical procedure, an open biopsy, or a significant traumatic injury within 28 days prior to treatment.
- Current or recent use (within 28 days) of a thrombolytic agent.
- Current use of full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous (i.v.) catheters; for patients receiving warfarin, the international normalized ratio [INR] should be <1.5), heparin or fractionated heparin are excluded.
- Chronic daily treatment with aspirin (>325 mg/day), nonsteroidal antiinflammatory or other medications known to inhibit platelet function (cyclooxygenase-2 [COX-2] inhibitors are permitted).
- A history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) within 6 months prior to study entry.
- Proteinuria ≥2+ by routine urinalysis or dipstick and subsequent documentation by 24-hour urine collection of >1 g protein. Patients with genitourinary malignancies and/or those with a requirement for urinary catheters or stents will be excluded if the 24-hour urine protein is ≥2 g.
- Pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG]) or breast feeding.
- Positive for anti-IMC-18F1 antibodies.
- Treatment with monoclonal antibodies within 6 weeks of study entry.
- A history of allergic reactions to monoclonal antibodies or other therapeutic proteins.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMC-18F1
|
Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period.
Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy.
Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy.
The starting dose in Cohort 1 will be 2mg/kg.
The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks.
Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period.
Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period.
No intrapatient dose escalation is allowed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Tolerated Dose
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics
Time Frame: 6 weeks
|
6 weeks
|
Antitumor Activity of IMC-18F1 Monotherapy
Time Frame: 6 Weeks
|
6 Weeks
|
Pharmacodynamics
Time Frame: 6 Weeks
|
6 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: E-mail: ClinicalTrials@ ImClone.com, Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2006
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
November 1, 2009
Study Registration Dates
First Submitted
October 27, 2008
First Submitted That Met QC Criteria
October 28, 2008
First Posted (Estimate)
October 29, 2008
Study Record Updates
Last Update Posted (Estimate)
September 30, 2010
Last Update Submitted That Met QC Criteria
September 29, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13941
- CP14-0501 (Other Identifier: ImClone, LLC)
- I4Y-IE-JCDA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on IMC-18F1
-
Eli Lilly and CompanyCompletedRectal Cancer | Colon CancerUnited States, Canada
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedCarcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal PelvisUnited States, Canada
-
Eli Lilly and CompanyCompletedMalignant MelanomaUnited States
-
ImmuneOncia Therapeutics Inc.RecruitingAdvanced CancerKorea, Republic of
-
ImmuneOncia Therapeutics Inc.CompletedLymphoma | Solid TumorKorea, Republic of, United States
-
ImmuneOncia Therapeutics Inc.Not yet recruitingA Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
-
Innovative Med Concepts, LLCCompletedChronic Pain | Fibromyalgia | Myofascial PainUnited States
-
Eli Lilly and CompanyCompletedNeoplasms | Neoplasm MetastasisUnited States
-
Immunocore LtdRecruitingSelect Advanced Solid TumorsUnited States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland